Le Lézard
Classified in: Health
Subjects: PDT, PLW

SOMAVAC® Medical Granted US Patent


MEMPHIS, Tenn., Aug. 24, 2021 /PRNewswire/ -- SOMAVAC® Medical Solutions, Inc. announces the granting of US Patent (11,078,898), covering its SOMAVAC® SVS Smart Suction Technology and surgical drain management platform. The SOMAVAC® SVS is the ONLY smart surgical drain pump cleared by the FDA to prevent seromas in plastic and general surgery. Most commonly used for mastectomies, breast reconstructions, hernia repairs, tummy tucks and complex orthopaedic procedures, the SOMAVAC® SVS applies continuous suction to surgical drains for effective removal of fluids and may reduce the risk of seromas or hematomas. Seromas/hematomas can lead to complications like infection, delayed wound healing and revision surgery.  

Each year since 1970, millions of patients have been discharged with manual JP bulbs and accordion-style suction devices. These manual devices are inconsistent in applying suction and ineffective at removing fluid, leading to stagnation, fluid build-up and backflow issues. Approximately 20% of these patients experience complications requiring painful and expensive interventions costing an estimated $6B to U.S. healthcare. Hence, the need for SOMAVAC® SVS smart continuous suction and one-way valve that minimizes stagnation, fluid build-up and backflow.

"The SOMAVAC® SVS is especially critical for our most vulnerable patients with breast and other cancer surgeries. If a cancer patient develops a complicated seroma and an infection, it can delay other life-saving treatments and result in a poor outcome," said Esra Roan, PhD, Co-founder and CEO of SOMAVAC® Medical. 

The longer the surgical drains and bulbs remain in place, the higher the risk of infection becomes for the patient. For patients with a mastectomy and immediate breast reconstruction with tissue expanders, the risk of infection increases to almost 25%, indicating one in four patients will get an infection after three weeks with drains*. SOMAVAC® SVS delivers robust suction that has been shown to shorten time with drains*.

The SOMAVAC® SVS can be discretely worn under clothing and can help patients return to normal activities while recovering. "SOMAVAC® SVS has really filled a void in drain technology. Their thoughtful approach to continuous, reliable suction will revolutionize post-operative drain management and lead to improvements in surgical outcomes," said Mark Brzesienski, MD, Chairman of Plastic Surgery at UTHSC, Chattanooga, TN.     

"This patent anchors our intellectual property portfolio. I am grateful to our outstanding team members and service providers for diligently pursuing this patent," said Josh Herwig, co-founder and CTO of SOMAVAC® Medical.

"This is only the beginning. Our patent gives our team the latitude to advance our technology and pursue innovative solutions that will further enhance the clinical outcomes and improve the recovery experience," said Esra Roan.  

For additional information: Visit www.somavacmedical.com, www.somavac.com

Indications: The SOMAVAC® SVS indicated for use in large surgical flaps in plastic and general surgery. Prescription only.

* Data on file

CONTACT: Esra Roan, CEO: [email protected] or (833) 766-2822

Related Images

surgical-drains.jpg
Surgical Drains
Left Image: Manual JP Bulbs designed in the 1970s. Right Image: SOMAVAC SVS Smart Vac System

SOURCE SOMAVAC Medical Solutions, Inc.


These press releases may also interest you

at 07:05
Av?sis and Harmony Health have joined forces to bridge oral healthcare gaps for underserved Medicaid populations with special healthcare needs. The pilot aims to revolutionize preventive dentistry by harnessing the power of real-time salivary testing...

at 07:05
United Therapeutics Corporation , announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024. A press release detailing the quarterly results will be issued that day at approximately...

at 07:05
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. , today announced that positive results from the Phase 3 oral zoliflodacin trial will be highlighted in an oral presentation given by the Global Antibiotic Research & Development...

at 07:03
As more and more consumers search for wellness products, particularly in the area of gut health, recent research from the North Carolina A&T University and existing medical publications confirm that nearly all brewed coffee is a significant source of...

at 07:00
Tilray Brands, Inc. , a leading global cannabis-lifestyle and consumer packaged goods company today announced the release of new cannabis flower products added to the Good Supply® ?Bud Squad'. Good Supply's signature Bud Squad product campaign was...

at 07:00
LSL PHARMA GROUP INC. (the "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, today announced the second and final tranche of its private placement financing of Units (as defined hereafter) for $3.8 million representing...



News published on and distributed by: